Homology Medicines (FIXX) Stock Price, News & Analysis

Company Overview

Homology Medicines, Inc. was a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare diseases. The company sought to use its proprietary human-derived adeno-associated virus vectors, known as AAVHSCs, to deliver gene therapies in vivo and address the underlying causes of inherited disorders.

Its development programs included HMI-103, an investigational gene therapy for phenylketonuria, as well as earlier programs targeting other rare diseases. Homology also explored the use of its platform for gene editing and other genetic medicine applications.

Homology Medicines was based in the United States and focused primarily on developing therapies for international rare-disease markets. In 2024, it combined with Q32 Bio, after which the combined business operated as Q32 Bio rather than as an independent Homology Medicines company.

Key Stats

• Today's Range: $12.73 to $13.50
• 50-Day Range: N/A
• 52-Week Range: $12.02 to $14.30
• Volume: 978 shs
• Average Volume: 1,230 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: BATS
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: BATS:FIXX
• CIK: N/A
• Web: www.homologymedicines.com
• Phone: (781) 301-3000
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: N/A
• Beta: N/A